Arbutus Biopharma Corporation (NASDAQ:ABUS) is one of the 10 Most Profitable Small Cap Stocks to Buy.
On May 13, 2026, Arbutus Biopharma Corporation (NASDAQ:ABUS) reported Q1 2026 revenue of $179.1 million with estimated license revenue tied to its litigation settlement with Moderna
The company said revenue jumped from $1.8 million a year earlier because of the increase in its share of a noncontingent settlement payment through Genevant Sciences. Arbutus Biopharma Corporation (NASDAQ:ABUS) reported net income of $169.7 million from a $24.5 million loss. The research and development expenses dropped to $4.1 million from $9.0 million with cost reductions and lower trial activity.
General and administrative expenses edged higher to $5.9 million due to legal costs, the company added. Separately, the firm said the US Food and Drug Administration granted Fast Track designation to imdusiran. It noted that the program could speed up development and review timelines.